

FILED ELECTRONICALLY

PATENT APPLICATION

Docket: 15070.6.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
)
	B. Ron Johnson)
)
Serial No.:	10/816,571) Art Unit
) 1614
Filed:	April 1, 2004)
)
Confirmation No.:	1232)
)
For:	ANTI-INFECTIVE COMPOSITIONS, METHODS AND)
	SYSTEMS FOR TREATING PATHOGEN-INDUCTED)
	DISORDERED TISSUES)
)
Examiner:	Donna A. Jagoe)
)
Customer No.:	022913)

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement dated April 14, 2009, Applicant respectfully submits the following to be filed in the above-identified application.

The Examiner has requested (i) an election of an invention to be examined and (ii) identification of the claims encompassing the elected invention. The Examiner has identified the inventions as follows:

- I. Claims 37-47 and 53-71, drawn to a method of treating pathogen disordered tissue comprising an organohalide compound, classified in class 514, subclass 643.
- II. Claims 48 and 50-52, drawn to a method of treating a pathogen disordered tissues comprising an organohalide compound and wherein the treatment composition is

substantially free of oils or other tissue penetration inhibiting components, classified in class 514, subclass 553-556.


- III. Claim 49, drawn to a method of treating a pathogen disordered tissues comprising an organohalide compound and wherein the treatment composition is substantially free of oils or other tissue penetration inhibiting components and substantially free of menthol, thymol, eucalyptol, eugenol, camphor, hexetidine and anethol, classified in class 514, subclass 553-556.

The Applicant hereby elects with traverse Invention I, which encompasses claims 37-47 and 53-71, and which is also generic to the other species or subcombinations in the Restriction Requirement. Because the elected group of claims also renders on the non-elected groups, Applicant respectfully traverses this Restriction Requirement.

The Commissioner is hereby authorized to charge payment of any of the following fees that may be applicable to this communication, or credit any overpayment, to **Deposit Account No. 23-3178**: (1) any filing fees required under 37 CFR § 1.16; (2) any patent application and reexamination processing fees under 37 CFR § 1.17; and/or (3) any post issuance fees under 37 CFR § 1.20. In addition, if any additional extension of time is required, which has not otherwise been requested, please consider this a petition therefore and charge any additional fees that may be required to **Deposit Account No. 23-3178**.

Dated this 11th day of May 2009.

Respectfully submitted,



JOHN M. GUYNN
Attorney for Applicant
Registration No. 36,153
Customer No. 022913